CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc.

CASI · Nasdaq

CASI Pharmaceuticals, Inc. (CASI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for CASI Pharmaceuticals, Inc. in 2026.

Earnings calendar

Next earnings date

—

Not scheduled

EPS estimate

—

Revenue estimate

—

Past earnings

29 Apr 2026
EPS actual
—
estimate -0.36
Revenue actual
—
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
14 Nov 2025
EPS actual
-0.68 (-70.0%)
estimate -0.40
Revenue actual
3.1M
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
David A. Cory
Employees
233
IPO date
12 Jun 1996
ISIN
KYG1933S1012
Website
casipharmaceuticals.com

Frequently asked questions

What was CASI Pharmaceuticals, Inc.'s most recent earnings date?

CASI Pharmaceuticals, Inc. (CASI) last reported earnings on April 29, 2026.

Where is CASI Pharmaceuticals, Inc. stock listed?

CASI Pharmaceuticals, Inc. (CASI) is listed on Nasdaq.